Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EquasensFRA:PHF 93 Forward PE Ratio is 17.65 as of Jul. 23, 2026. GuruFocus rates FRA:PHF with a GF Score™ of 93/100 and a GF Value™ of €91.11. The stock has 3 warning signs investors should review. Among 313 Healthcare Providers & Services companies, Equasens ranks better than 79.87% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Equasens Forward PE Ratio Related Terms
Equasens Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Equasens's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equasens Forward PE Ratio Chart
Equasens Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
17.83
18.07
Equasens Semi-Annual Data
2024-12
2025-06
2025-12
Forward PE Ratio
17.83
18.76
18.07
FRA:PHF vs VEEV, BTSG, TEM: Forward PE Ratio Comparison
For the Health Information Services subindustry, Equasens's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Equasens's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Equasens (FRA:PHF) has a Forward PE Ratio of 17.65 as of Jul. 23, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Equasens and its competitors. According to the industry distribution chart, Equasens ranks #63 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 20.1%.
Is Equasens' Forward PE Ratio too high?
Equasens' current Forward PE Ratio is 17.65. The Healthcare Providers & Services industry median Forward PE Ratio is 18.42. Equasens' value of 17.65 is 4.2% below this industry median. Based on the distribution chart, Equasens ranks #63 out of 313 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #63 out of 313 companies for Forward PE Ratio. This places Equasens in the top 20% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 18.42. Equasens' value of 17.65 is 4.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.42, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current Forward PE Ratio of 17.65 is 4.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current Forward PE Ratio is 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current Forward PE Ratio of 17.65. The stock's GF Value™ is €91.11, compared to a current price of €52.77 — trading 42.1% below its estimated fair value. The current Forward PE Ratio is 17.65 and 4.2% below the Healthcare Providers & Services industry median of 18.42. Equasens' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Equasens (FRA:PHF), the current Forward PE Ratio is 17.65 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 42.1% below its estimated GF Value™ of €91.11.
Key valuation signals for FRA:PHF:
Forward PE Ratio: 17.65
GF Value™: €91.11 vs. price of €52.77 (42.1% below fair value)
Industry Position: 4.2% below the Healthcare Providers & Services median (#63 of 313)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
93GF Score
Get the complete analysis for FRA:PHF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
